open access

Vol 69, No 2 (2018)
Original paper
Published online: 2018-03-29
Submitted: 2017-07-13
Accepted: 2017-08-03
Get Citation

Sexual functioning and depressive symptoms in women with various types of prediabetes — a pilot study

Robert Krysiak, Agnieszka Drosdzol-Cop, Violetta Skrzypulec-Plinta, Bogusław Okopień
DOI: 10.5603/EP.2018.0021
·
Pubmed: 29952425
·
Endokrynologia Polska 2018;69(2):175-181.

open access

Vol 69, No 2 (2018)
Original Paper
Published online: 2018-03-29
Submitted: 2017-07-13
Accepted: 2017-08-03

Abstract

Introduction: No previous study has investigated sexual functioning in prediabetic women. Aim: This study was aimed at investigating sexual function in young women with various types of prediabetes. Methods: The study included four groups of women: women with isolated impaired fasting glucose (Group A; n=19), isolated impaired glucose tolerance (Group B; n=18), presence of both impaired fasting glucose and impaired glucose tolerance (Group C; n=18), as well as matched healthy controls (Group D; n=19). All participants completed questionnaires evaluating sexual function (Female Sexual Function Index - FSFI) and the presence and severity of depressive symptoms (Beck Depression Inventory-Second Edition – BDI-II). Results: The total FSFI and BDI-II scores were lower in Group C than in the remaining groups of women, while the total FSFI score was lower in Groups A and B than in Group D. Patients with both impaired fasting glucose and impaired glucose tolerance had lower scores in all domains (sexual desire, arousal, lubrication, orgasm, sexual satisfaction and dyspareunia). Compared to Group D, Group A was characterized by lower domain scores for sexual desire and sexual satisfaction, while Group B by lower domain scores for desire, arousal and orgasm. In all groups of prediabetic women, the overall FSFI score correlated negatively with the degree of insulin resistance and weakly with the total BDI-II score. Conclusions: Impaired fasting glucose and impaired glucose tolerance may disturb sexual functioning and induce depressive symptoms.

Abstract

Introduction: No previous study has investigated sexual functioning in prediabetic women. Aim: This study was aimed at investigating sexual function in young women with various types of prediabetes. Methods: The study included four groups of women: women with isolated impaired fasting glucose (Group A; n=19), isolated impaired glucose tolerance (Group B; n=18), presence of both impaired fasting glucose and impaired glucose tolerance (Group C; n=18), as well as matched healthy controls (Group D; n=19). All participants completed questionnaires evaluating sexual function (Female Sexual Function Index - FSFI) and the presence and severity of depressive symptoms (Beck Depression Inventory-Second Edition – BDI-II). Results: The total FSFI and BDI-II scores were lower in Group C than in the remaining groups of women, while the total FSFI score was lower in Groups A and B than in Group D. Patients with both impaired fasting glucose and impaired glucose tolerance had lower scores in all domains (sexual desire, arousal, lubrication, orgasm, sexual satisfaction and dyspareunia). Compared to Group D, Group A was characterized by lower domain scores for sexual desire and sexual satisfaction, while Group B by lower domain scores for desire, arousal and orgasm. In all groups of prediabetic women, the overall FSFI score correlated negatively with the degree of insulin resistance and weakly with the total BDI-II score. Conclusions: Impaired fasting glucose and impaired glucose tolerance may disturb sexual functioning and induce depressive symptoms.
Get Citation

Keywords

depressive symptoms, impaired fasting glucose, impaired glucose tolerance, sexual functioning

About this article
Title

Sexual functioning and depressive symptoms in women with various types of prediabetes — a pilot study

Journal

Endokrynologia Polska

Issue

Vol 69, No 2 (2018)

Article type

Original paper

Pages

175-181

Published online

2018-03-29

DOI

10.5603/EP.2018.0021

Pubmed

29952425

Bibliographic record

Endokrynologia Polska 2018;69(2):175-181.

Keywords

depressive symptoms
impaired fasting glucose
impaired glucose tolerance
sexual functioning

Authors

Robert Krysiak
Agnieszka Drosdzol-Cop
Violetta Skrzypulec-Plinta
Bogusław Okopień

References (42)
  1. Twigg SM, Kamp MC, Davis TM, et al. Australian Diabetes Society, Australian Diabetes Educators Association. Prediabetes: a position statement from the Australian Diabetes Society and Australian Diabetes Educators Association. Med J Aust. 2007; 186(9): 461–465.
  2. Petersen JL, McGuire DK. Impaired glucose tolerance and impaired fasting glucose--a review of diagnosis, clinical implications and management. Diab Vasc Dis Res. 2005; 2(1): 9–15.
  3. Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care. 2006; 29(5): 1130–1139.
  4. Abdul-Ghani M, DeFronzo RA, Jayyousi A, et al. Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am J Cardiol. 2011; 108(3 Suppl): 3B–324B.
  5. Edelstein SL, Knowler WC, Bain RP, et al. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes. 1997; 46(4): 701–710.
  6. Vaccaro O, Ruffa G, Imperatore G, et al. Risk of diabetes in the new diagnostic category of impaired fasting glucose: a prospective analysis. Diabetes Care. 1999; 22(9): 1490–1493.
  7. Rutte A, van Splunter MMI, van der Heijden AA, et al. Prevalence and Correlates of Sexual Dysfunction in Men and Women With Type 2 Diabetes. J Sex Marital Ther. 2015; 41(6): 680–690.
  8. Shi YF, Shao XYu, Lou QQ, et al. Study on female sexual dysfunction in type 2 diabetic Chinese women. Biomed Environ Sci. 2012; 25(5): 557–561.
  9. Veronelli A, Mauri C, Zecchini B, et al. Sexual dysfunction is frequent in premenopausal women with diabetes, obesity, and hypothyroidism, and correlates with markers of increased cardiovascular risk. A preliminary report. J Sex Med. 2009; 6(6): 1561–1568.
  10. Yencilek F, Attar R, Erol B, et al. Factors affecting sexual function in premenopausal age women with type 2 diabetes: a comprehensive study. Fertil Steril. 2010; 94(5): 1840–1843.
  11. Pontiroli AE, Cortelazzi D, Morabito A. Female sexual dysfunction and diabetes: a systematic review and meta-analysis. J Sex Med. 2013; 10(4): 1044–1051.
  12. Martelli V, Valisella S, Moscatiello S, et al. Prevalence of sexual dysfunction among postmenopausal women with and without metabolic syndrome. J Sex Med. 2012; 9(2): 434–441.
  13. Alvisi S, Baldassarre M, Lambertini M, et al. Sexuality and psychopathological aspects in premenopausal women with metabolic syndrome. J Sex Med. 2014; 11(8): 2020–2028.
  14. Esposito K, Ciotola M, Marfella R, et al. The metabolic syndrome: a cause of sexual dysfunction in women. Int J Impot Res. 2005; 17(3): 224–226.
  15. Kim YH, Kim SM, Kim JJu, et al. Does metabolic syndrome impair sexual function in middle- to old-aged women? J Sex Med. 2011; 8(4): 1123–1130.
  16. Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000; 26(2): 191–208.
  17. Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther. 2005; 31(1): 1–20.
  18. Ferenidou F, Kapoteli V, Moisidis K, et al. Presence of a sexual problem may not affect women's satisfaction from their sexual function. J Sex Med. 2008; 5(3): 631–639.
  19. Beck AT, Steer RA, Brown GK. BDI-II: Beck Depression Inventory Manual. 2nd ed. Psychological Corporation, San Antonio 1996.
  20. American Psychiatric Association. Diagnostic and statistical manual of mental disorders — DSM-IV-TR. 4th ed. American Psychiatric Publishing, Washington 1994.
  21. Chan DC, Barrett PH, Watts GF. The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia. Best Pract Res Clin Endocrinol Metab. 2014; 28(3): 369–385.
  22. Krysiak R, Okopien B. The effect of fenofibrate on lymphocyte cytokine release in patients with impaired fasting glucose and impaired glucose tolerance: a preliminary report. Atherosclerosis. 2010; 213(1): 325–328.
  23. Krysiak R, Gdula-Dymek A, Bachowski R, et al. Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes. Diabetes Care. 2010; 33(10): 2266–2270.
  24. Krysiak R, Gdula-Dymek A, Okopień B. Hemostatic effects of simvastatin in subjects with impaired fasting glucose. Pharmacol Rep. 2010; 62(6): 1090–1098.
  25. Krysiak R, Okopien B. Haemostatic effects of simvastatin in subjects with impaired glucose tolerance. Intern Med J. 2011; 41(6): 473–481.
  26. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006; 86(2): 515–581.
  27. Kher N, Marsh JD. Pathobiology of atherosclerosis--a brief review. Semin Thromb Hemost. 2004; 30(6): 665–672.
  28. Wilson HM, Barker RN, Erwig LP. Macrophages: promising targets for the treatment of atherosclerosis. Curr Vasc Pharmacol. 2009; 7(2): 234–243.
  29. Weyand CM, Younge BR, Goronzy JJ. T cells in arteritis and atherosclerosis. Curr Opin Lipidol. 2008; 19(5): 469–477.
  30. Hansson GK. Inflammatory mechanisms in atherosclerosis. J Thromb Haemost. 2009; 7 Suppl 1: 328–331.
  31. Krysiak R, Okopień B, Herman Z. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs. 2003; 63(17): 1821–1854.
  32. Sprague RS, Ellsworth ML. Vascular disease in pre-diabetes: new insights derived from systems biology. Mo Med. 2010; 107(4): 265–269.
  33. Knowler WC, Barrett-Connor E, Fowler SE, et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346(6): 393–403.
  34. Krysiak R, Okrzesik J, Okopien B. The effect of short-term metformin treatment on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance: a pilot study. Endocrine. 2015; 49(1): 242–249.
  35. Krysiak R, Kowalcze K, Szkrobka W, et al. The effect of metformin on prolactin levels in patients with drug-induced hyperprolactinemia. Eur J Intern Med. 2016; 30: 94–98.
  36. Banaszewska B, Pawelczyk L, Spaczynski RZ, et al. Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. J Clin Endocrinol Metab. 2011; 96(11): 3493–3501.
  37. Barba M, Schünemann HJ, Sperati F, et al. The effects of metformin on endogenous androgens and SHBG in women: a systematic review and meta-analysis. Clin Endocrinol (Oxf). 2009; 70(5): 661–670.
  38. Krysiak R, Okopien B. The effect of metformin on androgen production in diabetic women with non-classic congenital adrenal hyperplasia. Exp Clin Endocrinol Diabetes. 2014; 122(10): 568–571.
  39. Krysiak R, Drosdzol-Cop A, Skrzypulec-Plinta V, et al. Sexual function and depressive symptoms in young women with elevated macroprolactin content: a pilot study. Endocrine. 2016; 53(1): 291–298.
  40. Krysiak R, Drosdzol-Cop A, Skrzypulec-Plinta V, et al. Sexual function and depressive symptoms in young women with thyroid autoimmunity and subclinical hypothyroidism. Clin Endocrinol (Oxf). 2016; 84(6): 925–931.
  41. Zunszain PA, Hepgul N, Pariante CM. Inflammation and depression. Curr Top Behav Neurosci. 2013; 14: 135–151.
  42. Waugh NR, Shyangdan D, Taylor-Phillips S, et al. Screening for type 2 diabetes: a short report for the National Screening Committee. Health Technol Assess. 2013; 17(35): 1–90.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl